monitoring patients on antipsychotics for obesity, diabetes, and dyslipidemia
March 2002
You'll see more focus on monitoring patients on antipsychotics for obesity, diabetes, and dyslipidemia.
Both the older antipsychotics (Thorazine, etc) and the newer "atypical" antipsychotics (Clozaril, Zyprexa, etc) can increase the risk of weight gain, diabetes, or changes in lipid levels.
Weight gain. Thorazine, Clozaril, and Zyprexa seem to cause the most. It happens with other antipsychotics, but not as much.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote